Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Lymphoproliferative Disorders

ClinicalTrials.gov lists 14,435 trials for Lymphoproliferative Disorders or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 620.

MeSH D008232 Hemic and Lymphatic Diseases C15 C20 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 3,200 Phase 1/2 Phase 1/2 1,628 Phase 2 Phase 2 4,383 Phase 2/3 Phase 2/3 165 Phase 3 Phase 3 1,171 Phase 4 Phase 4 293 Not applicable Not applicable 1,411 Observational Observational 2,110 Phase 1 Phase 1 3,200 Phase 1/2 Phase 1/2 1,628 Phase 2 Phase 2 4,383 Phase 2/3 Phase 2/3 165 Phase 3 Phase 3 1,171 Phase 4 Phase 4 293 Not applicable Not applicable 1,411 Observational Observational 2,110

Trials per phase (log scale)

2 more sections with rows

202 of the 14,435 trials are tagged with Lymphoproliferative Disorders itself; the rest are tagged with a narrower condition beneath it.

Get the Lymphoproliferative Disorders report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Lymphoproliferative Disorders trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 38 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access, Unknown)

Top of scale: 775

1990: 11 trials (Observational 1, Not applicable 1, Phase 2/3 1, Phase 2 6, Phase 1 2) 1991: 9 trials (Observational 2, Not applicable 1, Phase 2 4, Phase 1 2) 1992: 14 trials (Observational 2, Phase 3 2, Phase 2 7, Phase 1/2 1, Phase 1 2) 1993: 22 trials (Observational 3, Not applicable 1, Phase 4 1, Phase 3 5, Phase 2 10, Phase 1 2) 1994: 29 trials (Observational 4, Phase 3 10, Phase 2 11, Phase 1 4) 1995: 54 trials (Observational 5, Not applicable 1, Phase 4 3, Phase 3 11, Phase 2/3 1, Phase 2 20, Phase 1/2 5, Phase 1 8) 1996: 69 trials (Observational 8, Not applicable 3, Phase 4 2, Phase 3 13, Phase 2 28, Phase 1/2 2, Phase 1 13) 1997: 88 trials (Observational 8, Not applicable 4, Phase 4 1, Phase 3 18, Phase 2/3 1, Phase 2 33, Phase 1/2 4, Phase 1 19) 1998: 133 trials (Observational 8, Not applicable 6, Phase 4 1, Phase 3 19, Phase 2/3 1, Phase 2 64, Phase 1/2 9, Phase 1 25) 1999: 162 trials (Observational 10, Not applicable 7, Phase 4 1, Phase 3 23, Phase 2/3 2, Phase 2 67, Phase 1/2 13, Phase 1 39) 2000: 202 trials (Observational 16, Not applicable 18, Phase 4 5, Phase 3 37, Phase 2/3 5, Phase 2 83, Phase 1/2 16, Phase 1 22) 2001: 179 trials (Observational 11, Not applicable 14, Phase 4 3, Phase 3 25, Phase 2/3 6, Phase 2 69, Phase 1/2 18, Phase 1 33) 2002: 220 trials (Observational 17, Not applicable 15, Phase 4 3, Phase 3 23, Phase 2/3 3, Phase 2 101, Phase 1/2 25, Phase 1 33) 2003: 255 trials (Observational 16, Not applicable 21, Phase 4 10, Phase 3 47, Phase 2/3 3, Phase 2 89, Phase 1/2 31, Phase 1 38) 2004: 335 trials (Observational 26, Not applicable 22, Phase 4 10, Phase 3 31, Phase 2/3 6, Phase 2 148, Phase 1/2 29, Phase 1 63) 2005: 364 trials (Observational 35, Not applicable 21, Phase 4 6, Phase 3 35, Phase 2/3 2, Phase 2 159, Phase 1/2 38, Phase 1 68) 2006: 415 trials (Observational 36, Not applicable 19, Phase 4 10, Phase 3 41, Phase 2/3 2, Phase 2 171, Phase 1/2 50, Phase 1 86) 2007: 428 trials (Other 1, Observational 34, Not applicable 25, Phase 4 6, Phase 3 35, Phase 2/3 3, Phase 2 166, Phase 1/2 43, Phase 1 115) 2008: 460 trials (Observational 65, Not applicable 30, Phase 4 6, Phase 3 35, Phase 2/3 9, Phase 2 162, Phase 1/2 52, Phase 1 101) 2009: 425 trials (Other 2, Observational 60, Not applicable 24, Phase 4 9, Phase 3 45, Phase 2/3 6, Phase 2 155, Phase 1/2 43, Phase 1 81) 2010: 479 trials (Observational 64, Not applicable 30, Phase 4 15, Phase 3 35, Phase 2/3 6, Phase 2 156, Phase 1/2 66, Phase 1 107) 2011: 455 trials (Observational 75, Not applicable 25, Phase 4 7, Phase 3 40, Phase 2/3 1, Phase 2 160, Phase 1/2 51, Phase 1 96) 2012: 476 trials (Observational 65, Not applicable 31, Phase 4 9, Phase 3 49, Phase 2 156, Phase 1/2 56, Phase 1 110) 2013: 430 trials (Observational 59, Not applicable 32, Phase 4 14, Phase 3 47, Phase 2/3 5, Phase 2 109, Phase 1/2 51, Phase 1 113) 2014: 461 trials (Observational 51, Not applicable 43, Phase 4 11, Phase 3 38, Phase 2/3 3, Phase 2 119, Phase 1/2 72, Phase 1 124) 2015: 504 trials (Observational 69, Not applicable 37, Phase 4 14, Phase 3 44, Phase 2/3 6, Phase 2 164, Phase 1/2 64, Phase 1 106) 2016: 580 trials (Observational 89, Not applicable 40, Phase 4 16, Phase 3 32, Phase 2/3 15, Phase 2 166, Phase 1/2 80, Phase 1 142) 2017: 607 trials (Observational 94, Not applicable 54, Phase 4 9, Phase 3 48, Phase 2/3 6, Phase 2 160, Phase 1/2 87, Phase 1 149) 2018: 618 trials (Observational 93, Not applicable 56, Phase 4 10, Phase 3 31, Phase 2/3 3, Phase 2 183, Phase 1/2 78, Phase 1 164) 2019: 655 trials (Observational 111, Not applicable 68, Phase 4 18, Phase 3 42, Phase 2/3 8, Phase 2 159, Phase 1/2 72, Phase 1 177) 2020: 645 trials (Observational 138, Not applicable 74, Phase 4 7, Phase 3 32, Phase 2/3 7, Phase 2 160, Phase 1/2 61, Phase 1 166) 2021: 758 trials (Observational 134, Not applicable 99, Phase 4 12, Phase 3 47, Phase 2/3 4, Phase 2 191, Phase 1/2 89, Phase 1 182) 2022: 775 trials (Observational 147, Not applicable 125, Phase 4 18, Phase 3 47, Phase 2/3 5, Phase 2 164, Phase 1/2 90, Phase 1 179) 2023: 758 trials (Observational 160, Not applicable 122, Phase 4 14, Phase 3 42, Phase 2/3 7, Phase 2 158, Phase 1/2 98, Phase 1 157) 2024: 756 trials (Observational 153, Not applicable 115, Phase 4 14, Phase 3 39, Phase 2/3 6, Phase 2 202, Phase 1/2 73, Phase 1 154) 2025: 728 trials (Observational 130, Not applicable 112, Phase 4 15, Phase 3 40, Phase 2/3 17, Phase 2 203, Phase 1/2 78, Phase 1 133)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 671
2025 728
2024 756
2023 758
2022 775
2021 758
2020 645
2019 655
2018 618
2017 607

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 830 trials starting in 2026 and about 750 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 10 percent and ran about 4 percent high against the count later registered; forecasts made before the year began were off by about 25 percent and ran about 15 percent low against the count later registered, and had about 7 percent more error than repeating last year's count. The part-way figures are from forecasts that used a multiple fitted only on earlier years. A stricter check that trains only on older years did not support adding planned starts for conditions of this size: it ran about 6 percent high against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 1,871 trials still running at the 2026-10-09 snapshot; registered median of 40 months across 8,489 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Lymphoproliferative Disorders trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 3,200
Phase 1/2 1,628
Phase 2 4,383
Phase 2/3 165
Phase 3 1,171
Phase 4 293
Not applicable 1,411
Observational 2,110
Expanded access 73
Unknown 1

How many Lymphoproliferative Disorders trials are recruiting? (13)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 561
Recruiting 2,072
Enrolling by invitation 62
Active, not recruiting 1,085
Available 17

Showing 5 of 13 statuses.

Start your 14-day trial Email me all 13 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Lymphoproliferative Disorders trials? (7)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 620
Celgene 161
Novartis Pharmaceuticals 139
Hoffmann-La Roche 138
Children's Oncology Group 113

Showing 5 of 7 sponsors.

Start your 14-day trial Email me all 7 sponsors as a PDF

Which drugs are being tested for Lymphoproliferative Disorders? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Cytoxan 1,370
RITUXIMAB 1,218
Prednisone 484
Melphalan 399

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Dexamethasone/Dexamethasone acetate 1,076
SQ Fludarabine 711
X: Lenalidomide 679
Vincristina 585
Bortezomib SC 564

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Lymphoproliferative Disorders trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 9,412 909
Febrile neutropenia 7,176 857
Pyrexia 4,543 680
Sepsis 3,892 905
Neutrophil count decreased 3,695 328

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Lymphoproliferative Disorders? (156)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Patterns of belatacept use and risk of post-transplant lymphoproliferative disorder in US kidney transplant recipients: An analysis of the Organ Procurement and Transplantation Network database. PloS one 2025 Yes
Artificial intelligence-based flow cytometry for the diagnosis of B-cell chronic lymphoproliferative disorders. Blood advances 2025 Yes
Third-party virus-specific T cells for the treatment of double-stranded DNA viral reactivation and posttransplant lymphoproliferative disease after solid organ transplant. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2024 Yes
Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children's Oncology Group study. Blood advances 2024 Yes
Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial. The Lancet. Oncology 2024 Yes

Showing 5 of 156 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (4)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
X-linked lymphoproliferative disease Point prevalence <1 / 1 000 000 China Not stated Exact
X-linked lymphoproliferative disease Point prevalence <1 / 1 000 000 Europe Not stated Exact
X-linked lymphoproliferative disease Point prevalence <1 / 1 000 000 Europe Not stated Exact
X-linked lymphoproliferative disease Point prevalence <1 / 1 000 000 China Not stated Exact

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
X-linked lymphoproliferative disease 2442 Exact Orphadata Science knowledge files, Product 1
X-linked lymphoproliferative disease 2442 Exact Orphanet Rare Disease Ontology (ORDO)

Sub-conditions in MeSH (18)

MeSH descendants one level down with at least one trial, most trials first.

+8 more sub-conditions

Not on this page

Not measured: delivery record.

Browse all condition evidence pages